Nanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha

• Published in: International journal of nanomedicine Vol. 1; no. 4; pp. 399 - 409
• Main Authors: Zoller, Heinz, Vogel, Wolfgang
• Format: Journal Article
• Language: English
• Published: New Zealand Taylor & Francis Ltd 01.01.2006; Dove Medical Press
• Subjects: Acquired immune deficiency syndrome; AIDS; Antiretroviral drugs; Drug Carriers - chemistry; Genotype & phenotype; Hepatitis; Hepatitis C; Hepatitis C - complications; Hepatitis C - drug therapy; Hepatitis C virus; HIV; HIV Infections - complications; HIV Infections - drug therapy; Human immunodeficiency virus; Humans; Infections; Interferon; Interferon-alpha - chemistry; Interferon-alpha - therapeutic use; Liver cirrhosis; Nanomedicine - methods; Nanomedicine - trends; Polyethylene Glycols - chemistry; Review; Treatment Outcome

In immuno-competent individuals, the natural course of chronic hepatitis C virus (HCV) infection is highly variable and 5%-30% of patients develop cirrhosis over 20 years. Co-infection with HCV and human immunodeficiency virus (HIV) is an important prognostic factor and associated with more frequent...